Inflammatory Bowel Disease Journal Articles

• Shingles Prevention in Immunocompromised Dermatology Patients Many immunomodulatory medications used in dermatology can increase the risk of herpes zoster. Review the use of the recombinant zoster vaccine in patients receiving these drugs.
  Skin Therapy Letter, November 03, 2023
• Higher Dietary Fiber Intake and Risk of IBD This study investigated the association of dietary fiber intake from fruit, vegetable, bread, and cereal sources and incidence of IBD, Crohn's disease, and ulcerative colitis.
  Alimentary Pharmacology & Therapeutics, September 07, 2023
• Translating STRIDE-II Into Clinical Reality This paper explores the clinical implications and limitations of the 'treat-to-target' strategies which are recommended in the STRIDE-II consensus on inflammatory bowel diseases.
  Alimentary Pharmacology & Therapeutics, August 31, 2023
• Vedolizumab vs. Anti-TNF Agents in Biologic-naive UC Patients This study investigated the effectiveness of vedolizumab versus anti-TNF therapy in biologic-naive patients with ulcerative colitis at the end of induction therapy and during maintenance treatment.
  Alimentary Pharmacology & Therapeutics, August 29, 2023
• Factors Predicting Response to Low FODMAP Diet in IBS Are differences in fecal microbiota and/or fecal and urine metabolites associated with response to the low FODMAP diet in patients with irritable bowel syndrome?
  Alimentary Pharmacology & Therapeutics, August 24, 2023
• Medical Therapies for Treatment and Prevention of Pouchitis This review assessed the efficacy of medical therapies including antibiotics, probiotics, biologics, and fecal transplantation for the treatment and prevention of pouchitis following colectomy for UC.
  Alimentary Pharmacology & Therapeutics, August 10, 2023
• Biologics After Exposure to TNF Inhibitors in Ulcerative Colitis This study assessed the real-world efficacy of vedolizumab, ustekinumab and tofacitinib as second-line therapies in patients with ulcerative colitis who were previously exposed to a TNF inhibitor.
  Alimentary Pharmacology & Therapeutics, August 08, 2023
• Safety of Extended Interval Dosing ICIs A new study examines the safety of extended-interval dosing strategies in cancer patients receiving immune checkpoint inhibitors. Are they associated with a higher probability of adverse events?
  Journal of the National Cancer Institute, August 04, 2023
• Risk of IBD After Exposure to Broad-spectrum Antibiotics Is there a relationship between systemic antibiotic use and the risk of developing inflammatory bowel disease? Which classes of antibiotics are most implicated?
  Alimentary Pharmacology & Therapeutics, August 01, 2023
• Immunomodulators Increase Cervical Neoplasia Risk in IBD This study aimed to determine whether exposure to immunomodulators and/or biologics increase the risk of CIN2+ in women with inflammatory bowel disease.
  Alimentary Pharmacology & Therapeutics, July 25, 2023
• Elderly Onset IBD: Initiation of Medications, Risk of Surgery This study examined treatment strategies in patients with elderly onset IBD. Are IBD-specific medications underutilized in elderly patients?
  Alimentary Pharmacology & Therapeutics, July 13, 2023
• Switching From Humira(r) to Adalimumab Biosimilar in IBD Did switching to adalimumab biosimilar negatively impact patients' outcomes compared to maintaining treatment with the originator?
  Alimentary Pharmacology & Therapeutics, July 11, 2023
• Type 1 Diabetes and Microscopic Colitis Both microscopic colitis and type 1 diabetes are autoimmune diseases. Is there an association between the two?
  Alimentary Pharmacology & Therapeutics, July 06, 2023
• IBD and Cannabis: Key Counseling Strategies What should we be advising IBD patients regarding the use of cannabis? This case-based study explores ways to properly educate patients on the benefits and risks of its use.
  Current Opinion in Gastroenterology, July 04, 2023
• Colorectal Neoplasia Risk and Histologic Disease Activity in IBD Do colonic post-inflammatory polyps independently increase the risk of colorectal neoplasia occurrence in IBD patients, or is histologic activity a greater factor?
  Alimentary Pharmacology & Therapeutics, June 29, 2023
• Efficacy of TDM of Anti-TNF-therapy in IBD Does the use of therapeutic drug monitoring in inflammatory bowel disease patients on anti-TNF therapy result in improved outcomes?
  Alimentary Pharmacology & Therapeutics, June 27, 2023
• Effectiveness of Golimumab Intensification in Ulcerative Colitis Nearly 40% of patients with ulcerative colitis eventually fail to respond to golimumab treatment. Can therapeutic drug intensification recapture response?
  Alimentary Pharmacology & Therapeutics, June 20, 2023
• Migraine, Inflammatory Bowel Disease and Celiac Disease Is there a genetic link between migraine, inflammatory bowel disease, or celiac disease?
  Headache, June 20, 2023
• Brodalumab in Axial Spondyloarthritis Results from a phase 3 study show that brodalumab is a safe and effective potential treatment option for patients with axial spondyloarthritis.
  Rheumatology, June 15, 2023
• CV Risk in IBD Patients Receiving Small Molecule Drugs Does treatment with small molecule drugs such as JAK inhibitors and S1P modulators increase the risk of cardiovascular events in patients with inflammatory bowel disease?
  Alimentary Pharmacology & Therapeutics, June 13, 2023